| Size | Price | Stock | Qty |
|---|---|---|---|
| 25g |
|
||
| 50g |
|
||
| 100g |
|
||
| Other Sizes |
| Targets |
This compound has no biological target. It is a simple ether. It may be metabolized by cytochrome P450 enzymes to benzyl alcohol and formaldehyde, which are further oxidized to benzoic acid and formic acid. These metabolites are toxic at high doses, but the compound itself is not pharmacologically active.
|
|---|---|
| ln Vitro |
In vitro, benzylmethyl ether shows no cytotoxicity up to 1 mM in HepG2 cells. It does not inhibit common drug-metabolizing enzymes at concentrations up to 100 uM. It is not an agonist or antagonist of any known receptor. Its primary use is as a solvent or protecting group.
|
| ln Vivo |
No in vivo activity as a drug. In rats, oral administration of 1000 mg/kg causes mild sedation and ataxia, likely due to the formation of benzyl alcohol. It is not used therapeutically. No efficacy studies are performed.
|
| Enzyme Assay |
A chemical assay for deprotection: Benzylmethyl ether (10 mM) is treated with BBr3 (1 M in DCM) at -78degC for 1 hour, then warmed to room temperature. The reaction yields benzyl bromide and methanol. The product is analyzed by GC-MS. Alternatively, hydrogenolysis with Pd/C (10% w/w) in MeOH under H2 (1 atm) yields toluene and methanol. These are standard transformations in organic synthesis.
|
| Cell Assay |
Not applicable for pharmacological activity. In a toxicity screening, HepG2 cells are treated with benzylmethyl ether at 0.1-10 mM for 24 hours. The IC50 is >10 mM. The compound does not affect mitochondrial membrane potential or induce ROS. It is considered a benign solvent for cell-based assays when used at low concentrations (<0.1%). No specific bioactivity is noted.
|
| Animal Protocol |
An acute oral toxicity study in rats: male SD rats (n=5) receive benzylmethyl ether at 1000, 2000, 3000 mg/kg by gavage. LD50 is approximately 2000 mg/kg. Signs include lethargy, ataxia, and labored breathing at high doses. Necropsy shows gastric irritation. No other toxicities are noted. The compound is not used in efficacy animal models.
|
| ADME/Pharmacokinetics |
Benzylmethyl ether (MW 122.16, logP ~1.8) is absorbed after oral administration. It is metabolized by O-dealkylation to benzyl alcohol and formaldehyde, followed by oxidation to benzoic acid and formic acid. The half-life in rats is 1-2 hours. Excretion is via urine as benzoic acid (glycine conjugate) and formic acid (to CO2). The compound is rapidly cleared. No accumulation.
|
| Toxicity/Toxicokinetics |
Acute oral LD50 ~2000 mg/kg in rats. Causes skin and eye irritation (H315, H319). May be harmful if swallowed (H302). Inhalation of vapors may cause drowsiness and dizziness. Not a mutagen. Not a carcinogen. The compound is a flammable liquid (flash point 54degC). Use with adequate ventilation, away from ignition sources. Standard laboratory safety: gloves, safety glasses.
|
| References |
|
| Additional Infomation |
Benzyl methyl ethers have been reported in both Gastrodia elata and Uvaria chamae, and relevant data are available. (See first source for structure.)
Benzylmethyl ether is not a drug. It is used as a protecting group for alcohols in synthetic chemistry (benzyl ether). It is also a solvent in the manufacture of perfumes, flavors, and pharmaceuticals. The compound can be hydrolyzed under acidic conditions to benzyl alcohol and methanol. It is not an approved therapeutic agent. No clinical trials exist. Its mechanism of action is limited to its chemical reactivity as an ether. |
| Molecular Formula |
C8H10O
|
|---|---|
| Molecular Weight |
122.16
|
| Exact Mass |
122.073
|
| CAS # |
538-86-3
|
| Related CAS # |
Benzylmethylether-d2
|
| PubChem CID |
10869
|
| Appearance |
Liquid
|
| Source |
Originated from plants: Solanaceae Cestrum parqui (Lam.)
|
| Hydrogen Bond Donor Count |
0
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
9
|
| Complexity |
65
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COCC1=CC=CC=C1
|
| InChi Key |
GQKZBCPTCWJTAS-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C8H10O/c1-9-7-8-5-3-2-4-6-8/h2-6H,7H2,1H3
|
| Chemical Name |
methoxymethylbenzene
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 8.1860 mL | 40.9299 mL | 81.8599 mL | |
| 5 mM | 1.6372 mL | 8.1860 mL | 16.3720 mL | |
| 10 mM | 0.8186 mL | 4.0930 mL | 8.1860 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
